复宏汉霖(HENLIUS)最新发布的2025年财务报告显示,公司延续了稳健的增长态势,实现了营业收入与净利润的双双提升。在核心业务领域,公司持续推动创新药物的临床验证工作,并加速全球化商业布局,展现出强劲的发展动能。
复宏汉霖(HENLIUS)最新发布的2025年财务报告显示,公司延续了稳健的增长态势,实现了营业收入与净利润的双双提升。在核心业务领域,公司持续推动创新药物的临床验证工作,并加速全球化商业布局,展现出强劲的发展动能。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.